PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Expenditure Sub-Program Areas track more specific PEPFAR expenditures.
Object classes provide highly specific ways that implementing partners are spending PEPFAR funds on programming.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
Beneficiary Expenditure data identify how PEPFAR programming is targeted at reaching different populations.
Sub-Beneficiary Expenditure data highlight more specific populations targeted for HIV prevention and treatment interventions.
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
This is a new activity being proposed for the first time in FY 2007.
This award (#9742) was divided between 2 organizations (IntraHealth and UAB). A request is being made to update the Prime Partners, Targets and Activity Narratives. Funding and Targets have been divided up among the two partners. Also of note - the original target - Number tested and counselled was listed incorrectly. The orognal total amount for the entire activity should = 10,000 receiving CT rather than 18,000.
Voluntary Counseling and Testing (VCT) services have scaled-up in much of the country. There are many partners supporting this activity, however, it is very clear that the rural populations have not been adequately reached. The Zambia Voluntary Counseling and Testing (ZVCT) services coordinate most of the CT services in the country, both non-governmental organizations and government run centers. Of the 550 sites to date, very few cover the disadvantaged rural populations.
This activity will support mobile VCT services in two of the most underserved rural and remote districts Namwala in Southern Province and Luangwa District in Lusaka Province. These districts have been selected in consultation with the Provincial Health Office in the respective provinces.
Targets
Target Target Value Not Applicable Number of service outlets providing counseling and testing 4 according to national and international standards Number of individuals who received counseling and testing for HIV 6,000 and received their test results (including TB) Number of individuals trained in counseling and testing according to 20 national and international standards
Coverage Areas Lusaka
Southern
Table 3.3.10: Program Planning Overview Program Area: HIV/AIDS Treatment/ARV Drugs Budget Code: HTXD Program Area Code: 10 Total Planned Funding for Program Area: $ 27,035,895.00
Program Area Context:
Scaling-up anti-retroviral therapy (ART) is critical to achieving the USG/Zambia Five-Year Strategy objectives, with emphasis on ARV (anti-retroviral) drug procurement and enhancing the capacity of the supply chain management systems. Great progress was made in improving the availability of ARV drugs at the national level during FY 2005 and FY 2006.
With about one million Zambians living with HIV/AIDS and 200,000 of these persons requiring ART, the Government of the Republic of Zambia (GRZ) has prioritized making ART available to all Zambians in need—as evidenced by the August 2005 policy rendering all public sector ART services free of charge. Furthermore, the national ART Implementation Plan was evaluated and updated in FY 2006. Findings from the evaluation revealed a need to continue strengthening the ARV drug procurement practices and related supply chain. As of August 2006, there were approximately 65,000 ART patients, nearly double the number of patients a year ago.
In FY 2005 and 2006, USG and JSI/DELIVER took the lead, in close collaboration with GRZ, to facilitate the development of multi-year ARV drug forecasts and quantifications, now updated on a quarterly basis. This process included the development of the first national, long-term ARV drug procurement plan, encompassing procurements made by USG, GRZ, Global Fund for AIDS, Tuberculosis, and Malaria (GFATM) Principal Recipients [Ministry of Health (MOH) and Churches Health Association of Zambia (CHAZ)], and Clinton Foundation. These drugs are placed in the MOH central warehouse, Medical Stores Ltd. (MSL), for distribution to all accredited ART sites (governmental and non-governmental); there are approximately 126 accredited ART sites in Zambia. Furthermore, USG ART Track 1.0 partners [Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) and Catholic Relief Services/AIDS Relief (CRS)] also procure ARVs for the sites they directly support.
In addition to the accomplishments made in ARV procurement, the ARV supply chain was also significantly improved during FY 2006; JSI/DELIVER continued its strong role in coordinating and addressing ARV logistics system issues. Examples include: conducting the first national ARV supply chain design workshop, developing and implementing a national training of trainers program for the new ARV drug logistics system, and initiating the national roll-out of this new ARV drug system. All activities were completed in close collaboration with the MOH.
In FY 2007, USG will continue its strong relations with GRZ, GFATM, and Clinton Foundation to ensure that there is a sufficient, uninterrupted supply of ARV drugs available in all accredited ART sites. On behalf of USG, Partnership for Supply Chain Management Systems (SCMS) and Project TBD (to be awarded by USAID/Washington) will conduct ARV procurements and expand support to strengthen the ARV drug supply chain. SCMS will conduct the ARV drug procurements in the most timely manner possible, taking advantage of their regional supply depot in South Africa. This warehouse allows for timelier, consolidated ARV drug shipments. SCMS' other key role is to improve quality control processes by conducting continuous testing of purchased ARV drugs. To protect these ARV procurement investments, Project TBD will continue its coordination role of all in-country ARV procurements, train key personnel in the new ARV drug logistics system--including persons at the new MOH Logistics Management Unit (LMU), and supervise/monitor ARV logistics activities at district and service delivery levels to ensure adherence to sound logistics practices.
As compared to FY 2006 in which USG procured $16.426M worth of ARV drugs, in FY 2007, USG will significantly increase its commitment to provision of these life-extending medicines. USG is planning to procure a total of $20M worth of the following ARV drugs: Abacavir, Efavirenz, Lamivudine, Lopinavir-Ritonavir, Nelfinavir, Nevirapine, Stavudine, Tenofovir, and Zidovudine (purchases may change as additional ARV drugs are FDA-approved and registered in Zambia, as GFATM and Clinton Foundation ARV drug donations become solidified, and when GRZ changes the national ARV treatment protocols in
mid-2007). These specific ARV drugs, in conjunction with the ARV drugs procured by GFATM and Clinton Foundation, will go directly to MSL where all accredited ART sites (GRZ, faith-based hospitals, NGOs, and work-place/private sector) have access to these critical supplies. In addition, with FY 2007 and Track 1.0 funds, EGPAF and CRS are planning to purchase at least $8.6M and $3M of ARV drugs respectively for the sites that they directly support. It is estimated that the USG ARV procurements, totaling $34.6M, in addition to the GFATM and Clinton Foundation purchases, will enable Zambia to place 130,000 patients on ART by mid-2008.
Through the ARV drug procurements and development of the national ARV drug logistics system, it is anticipated that these activities will assist in achieving a sustainable national ART program following intensive PEPFAR support.
Table 3.3.10:
